先声药业与AbbVie达成SIM0500海外许可协议,最高可获10.55亿美元付款

财中社
14 Jan

财中社1月14日电先声药业(02096)发布公告,与AbbVie签订了关于研究性新候选药物SIM0500的海外许可选择权协议。根据协议,AbbVie将获得SIM0500的许可选择性权益,该药物目前正在中美两国针对复发或难治性多发性骨髓瘤患者进行临床I期研究。公司将从AbbVie收取首付款,以及最高10.55亿美元的选择性权益付款和里程碑付款。此外,基于该产品在大中华区以外地区的净销售额,公司将获得...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10